Nationwide Fund Advisors Otonomy, Inc. Transaction History

Nationwide Fund Advisors

  • $918 Million
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 01, 2018
SELL
$2.8 - $5.55 $103,331 - $204,817
-36,904 Closed
0 $0
Q2 2017

Aug 10, 2017
BUY
N/A
36,904
36,904 $696,000

About OTONOMY, INC.

OTIC Quotes by TradingView
  • Ticker OTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,990,400
  • Description
  • Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...
More about OTIC
Track This Portfolio

Track Nationwide Fund Advisors Portfolio

Follow Nationwide Fund Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nationwide Fund Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Nationwide Fund Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email